Comparison of serum and lithium-heparinate plasma for the accurate measurements of endogenous and exogenous morphine concentrations

Alexis Laux-Biehlmann,1 Nadja Gräfe,1,2 Jinane Mouheiche,1 Denise Stuber,1 Ingeborg D. Welters,2,3 François Delalande,4 Pierrick Poisbeau,1 Patrick Garnero,5 Marie-Hélène Metz-Boutigue,6 Francis Schneider7 & Yannick Goumon1
1CNRS UPR3212, Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique and University of Strasbourg, Strasbourg, France, 2Abteilung für Anaesthesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Giessen und Marburg, Standort Giessen, Giessen, Germany, 3Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK, 4Laboratoire de spectrométrie de masse BioOrganique, IPHC-DSA, Université de Strasbourg, CNRS UMR7178, 25 rue Becquerel, Strasbourg, France, 5Cisbio Bioassays, Codolet, France, 6Inserm U977, Biomaterials and Tissue Engineering, University of Strasbourg, France and 7Réanimation Médicale, Hôpitaux Universitaires, Faculté de Médecine and University of Strasbourg, Strasbourg, France

In addition to its presence in blood samples from morphine-treated patients and heroin addicts, morphine is endogenously synthesized from dopamine in mammals [1, 2]. However, the physiological relevance of endogenous morphine (eM) remains an open question. Several studies report an increase in eM in blood and urine samples in pathological conditions such as infection, inflammation, bulimia, anorexia and Parkinson’s disease [2, 3]. For example, eM concentrations reached on average 2.5 ng ml\(^{-1}\) in the serum of patients suffering from systemic infections (sepsis), whereas healthy donors and control patients displayed no or very low eM concentrations [4]. Therefore, quantification of endogenous and exogenous morphine is of great interest for both clinical and forensic analyses.

As both endogenous and exogenous morphine are present at low concentrations, the quantification method implemented must be very sensitive. Besides, no consensus yet exists regarding blood sample preparation for morphine measurement using ELISA. As lithium-heparinate (plasma) and serum samples are both routinely used in clinical practice, we compared the morphine concentrations using these two sampling methods.

This study was approved by our institutional review board for human experimentation (CPP no. 08/62-protocol no. IVD1 EUDRACT no. 2008-A01345-50). After informed consent, samples were collected from patients requiring clinical laboratory analyses. Blood from 80 patients was collected in two types of sampling tubes, as follows: (i) for serum analysis, blood was collected in dry tubes (BD, Plymouth, UK; SSTII 377615), and serum was obtained after centrifugation (4°C, 1500\(\times\)g, 10 min); and (ii) for plasma analysis, blood was collected in lithium-heparinate tubes (BD; LH-PSTII 367378, 17 i.u. ml\(^{-1}\)) and plasma was recovered after centrifugation (4°C, 1500g, 10 min). Collected serum and plasma were immediately stored at \(-80^\circ\text{C}\) (for 3 weeks to 3 months). Samples were thawed only once, 15 min prior to ELISA testing. In these conditions, no effect of freezing on morphine concentrations has been noticed. Both plasma and serum morphine concentrations were quantified using a morphine-specific ELISA kit (ref. 213-0480; Immunalysis, Pomona, CA, USA) [4]. No cross-reactivity has been observed for morphine metabolites (morphine-6-glucuronide, morphine-3-glucuronide and codeine) and 75 other compounds (related to eM biosynthesis pathway or not; see also kit’s datasheet). The plasma or serum samples were tested in duplicates (40 \(\mu\)l) at 21°C. The coefficient of variation values were between 0% and 8%. All samples with a higher coefficient of variation value were retested in order to obtain a coefficient of variation below or equal to 8%. Morphine standards (0–25 ng ml\(^{-1}\)) were diluted in phosphate-buffered saline containing 1% bovine serum albumin (PBS-BSA; pH 7.2; w/v) for serum samples and in PBS-BSA 1% containing lithium-heparinate (17 i.u. ml\(^{-1}\)) for plasma samples. The detection limit for morphine was 0.1 ng ml\(^{-1}\).

In a set of control experiments, known concentrations of morphine (0.28 and 11 ng ml\(^{-1}\)) were diluted in PBS,
concentration in serum samples ranged from 3.2 to 23.6 ng ml\(^{-1}\), whereas morphine was not detected in patients negative for eM in ELISA (n = 4) [4]. As expected, no morphine was detected in samples from four healthy donors.

Our results revealed that morphine concentrations were systematically higher in plasma compared with serum for 61 of 64 patients and thus indicate that lithium-heparinate samples give a more accurate quantification of morphine blood concentrations. The cause of such a difference in morphine quantification between serum and plasma using this specific ELISA kit is currently under investigation by our group and might involve morphine binding to blood proteins [5] other than serum albumin. In line with this possibility, morphine detection in the blood has been shown to be highly dependent on urea concentrations (chaotropic agent), suggesting a link between morphine-binding proteins and morphine bioavailability [5]. Likewise, lithium is also a chaotropic/denaturing agent; therefore, it might explain why this ELISA quantification method for morphine is more efficient in the presence of lithium.

The present results clearly demonstrate that to obtain accurate ELISA determinations of exogenous and endogenous morphine concentrations in the blood, the analysis should be carried out on lithium-heparinate plasma samples rather than serum samples.

**Figure 1**

Concentrations of morphine in serum expressed as a function of the corresponding morphine concentrations in plasma in critically ill patients (n = 56, triangles) and in morphine-treated patients (n = 8, crosses). Inset shows a higher magnification of the lower values. All patients below the dashed line exhibited higher concentrations of morphine in the plasma than in the serum.

**Competing Interests**

There are no competing interests to declare.
REFERENCES


RECEIVED
14 October 2011

ACCEPTED
13 January 2012

ACCEPTED ARTICLE PUBLISHED ONLINE
1 February 2012

CORRESPONDENCE
Dr Yannick Goumon, INCI, CNRS UPR3212; Institut des Neurosciences Cellulaires et Intégratives; 5, rue Blaise Pascal, F-67084 Strasbourg Cedex, France.
Tel.: +33 3 88 45 67 18
Fax: +33 3 88 60 16 64
E-mail: yannick.goumon@inserm.u-strasbg.fr